Longevity molecules ranked by human evidence, not by marketing budget
NMN, rapamycin, spermidine, taurine and metformin all get called breakthroughs. The published human literature behind them differs by more than a factor of a hundred.
Every longevity compound arrives with the same framing: a promising mechanism, animal data, and a supplement already in stock. The honest separator is how much of that work was done in people.
Counts pulled from PubMed on 2026-08-29. The dark bar is human studies.
| Molecule | All studies | Human studies | Human share |
|---|---|---|---|
| Collagen (skin) | 26 | 13 | 50% |
| Spermidine | 164 | 80 | 49% |
| Taurine | 672 | 217 | 32% |
| Nicotinamide riboside | 950 | 419 | 44% |
| NMN | 1,711 | 592 | 35% |
| Metformin | 1,612 | 1,004 | 62% |
| Rapamycin | 3,492 | 1,785 | 51% |
| Resveratrol | 21,601 | 9,689 | 45% |
Rapamycin carries 1,785 human papers. Spermidine carries 80. Both get discussed in the same breath as longevity interventions, and they are not in the same evidential universe.
NMN, the most heavily marketed of the group, sits at 592 human studies against 1,711 in total. That is a real literature, and it is far smaller than the confidence of the advertising around it. Nicotinamide riboside is close behind at 419.
Metformin is the trap in reading raw counts: 1,004 human papers, because it has been a prescription drug for decades. Its longevity evidence is a small subset of that total, not the whole of it.
How to use this
Use it to calibrate claims, not to pick a compound. A large count means the question has been asked often, not that the answer came back favourable. A small count means nobody can honestly tell you what happens in people at the dose being sold.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.